Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for SU011248 (Sunitinib)

1 Open Trial

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCURO1514

08/06/2015

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 ANTIBODY) in Combination with BEVACIZUMAB versus SUNITINIB in Patients with Untreated Advanced Renal Cell Carcinoma.